Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New fluid management strategy tested in ICU kidney patients

NCT ID NCT05473143

Knowledge-focused Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a proactive, prescription-based fluid management plan to usual care in 150 critically ill patients who need kidney replacement therapy (dialysis). The goal is to see if a standardized daily prescription can help achieve a neutral or negative fluid balance, preventing fluid buildup. The trial is a pilot, meaning it mainly tests whether the approach is feasible and can be followed consistently.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
protocol-based fluid management
What this could lead to
If successful, this could show that a simple daily prescription template helps doctors better manage fluid levels in critically ill patients on kidney dialysis, potentially reducing complications.
What could go wrong
This is a small pilot study (150 patients) focused on feasibility, not on proving better outcomes. The approach may not improve patient health or may be too complex for routine ICU use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years 2. Admitted to the ICU 3. AKI during current hospitalization defined by the Kidney Disease: Improving Global Outcomes (KDIGO) criteria(1) as any of the following: Increase in serum creatinine by 27 µmol/L or more within any 48-hour window, or an increase in serum creatinine to 1.5 times baseline or more within the last 7 days, or a urine output less than 0.5 mL/kg/h for 6 hours. 4. Planned initiation of KRT within the following 12 hours or the receipt of KRT for AKI for ≤48 hours Exclusion Criteria: 1. Lack of commitment to maintain kidney, pharmacologic or respiratory support at the time of screening, or probable transition to comfort care within 48 hours according to the treating physician 2. Probable discharge from the ICU within the next 48 hours according to treating physician 3. Severe burn injury (\>10% of body surface area) 4. Severe abnormality in serum sodium (\>155 or \<120 mmol/L) 5. Important ongoing fluid losses are present and/or are expected to require continued maintenance IV fluids uring the next 48 hours 6. The clinical care team believes that the proposed intervention is inappropriate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute kidney injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury Critical Illness

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute kidney injury Critical illness Kidney replacement

Contacts and locations

Locations

  • Centre Hospitalier de l'Université de Montréal

    Montreal, Quebec, H2X0A9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.